Acidity changes immunology: a new VISTA pathway

January 21, 2020


Nature Immunology  volume 21, pages13–16 (2020)


  • Using the LRC-TriCEPS platform  PSGL-1  was identified as the interaction partner of the co-inhibitor Vista on activated primary T-cells as at acidic pH mimicking the acidic tumour environment
  • Now, Vista tumour immunotherapy can rationally move  forward
  • The results also suggest to use also acidity as therapeutic target for tumour therapy
  • Now also other interactions at acidic pH for drug candidates or co-inhibitor interactions should be tested on primary T-cells. It could explain why some drug candidates are not successful in later development.


Kathleen M. Mahoney and Gordon J. Freeman